MCID: 47X002
MIFTS: 48

47,xyy

Categories: Fetal diseases, Mental diseases, Muscle diseases, Rare diseases

Aliases & Classifications for 47,xyy

MalaCards integrated aliases for 47,xyy:

Name: 47,xyy 73
Xyy Syndrome 73 20 43 58
Double Y Syndrome 20 58 29
47,xyy Syndrome 20 43 58
47, Xyy Syndrome 20 70
Xyy Karyotype 20 43
Yy Syndrome 20 43
Y Disomy 20 58
Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome 70
Jacob's Syndrome 43
Jacobs Syndrome 20
Disomy Y 20
Double Y 20

Characteristics:

Orphanet epidemiological data:

58
47,xyy syndrome
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Developmental anomalies during embryogenesis


Summaries for 47,xyy

MedlinePlus Genetics : 43 47,XYY syndrome is characterized by an extra copy of the Y chromosome in each of a male's cells. Although many males with this condition are taller than average, the chromosomal change sometimes causes no unusual physical features. Most males with 47,XYY syndrome have normal production of the male sex hormone testosterone and normal sexual development, and they are usually able to father children.47,XYY syndrome is associated with an increased risk of learning disabilities and delayed development of speech and language skills. Affected boys can have delayed development of motor skills (such as sitting and walking) or weak muscle tone (hypotonia). Other signs and symptoms of this condition include hand tremors or other involuntary movements (motor tics), seizures, and asthma. Males with 47,XYY syndrome have an increased risk of behavioral, social, and emotional difficulties compared with their unaffected peers. These problems include attention-deficit/hyperactivity disorder (ADHD); depression; anxiety; and autism spectrum disorder, which is a group of developmental conditions that affect communication and social interaction.Physical features related to 47,XYY syndrome can include increased belly fat, a large head (macrocephaly), unusually large teeth (macrodontia), flat feet (pes planus), fifth fingers that curve inward (clinodactyly), widely spaced eyes (ocular hypertelorism), and abnormal side-to-side curvature of the spine (scoliosis). These characteristics vary widely among affected boys and men.

MalaCards based summary : 47,xyy, also known as xyy syndrome, is related to turner syndrome and camptodactyly-arthropathy-coxa vara-pericarditis syndrome. An important gene associated with 47,xyy is IGFBP3 (Insulin Like Growth Factor Binding Protein 3). The drugs Nitroglycerin and Labetalol have been mentioned in the context of this disorder. Affiliated tissues include prostate, myeloid and bone marrow, and related phenotypes are delayed speech and language development and low-set ears

GARD : 20 47, XYY syndrome is a syndrome (group of signs and symptoms) that affects males. For some males with this syndrome, signs and symptoms are barely noticeable. For others, signs and symptoms may include learning disabilities, speech delay, low muscle tone ( hypotonia ), and being taller than expected. 47, XYY syndrome is caused by having an extra copy of the Y chromosome in every cell of the body. The syndrome is usually not inherited. Diagnosis can be made based on prenatal tests, or it may occur during childhood or adulthood if a male has signs or symptoms of the disease. Management may include special education as well as intervention or therapies for developmental delays.

Wikipedia : 73 XYY syndrome is a genetic condition in which a male has an extra Y chromosome. There are usually few... more...

Related Diseases for 47,xyy

Diseases related to 47,xyy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 turner syndrome 29.3 SRY IGFBP3
2 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 11.5
3 numeric sex chromosome variations 11.2
4 infertility 10.4
5 gonadal dysgenesis 10.4
6 48,xyyy 10.4
7 azoospermia 10.4
8 autism spectrum disorder 10.3
9 cryptorchidism, unilateral or bilateral 10.2
10 tooth size 10.2
11 gonadoblastoma 10.2
12 hypogonadotropic hypogonadism 10.2
13 mixed gonadal dysgenesis 10.2
14 chromosomal triplication 10.2
15 attention deficit-hyperactivity disorder 10.2
16 prader-willi syndrome 10.2
17 male infertility 10.2
18 hypogonadism 10.2
19 hypotonia 10.2
20 tremor 10.2
21 hair whorl 10.1
22 hypertelorism 10.1
23 down syndrome 10.1
24 taurodontism 10.1
25 fragile x syndrome 10.1
26 hypospadias 10.1
27 heart disease 10.1
28 synostosis 10.1
29 oligospermia 10.1
30 cystic lymphangioma 10.1
31 pseudohermaphroditism 10.1
32 learning disability 10.1
33 radioulnar synostosis 10.1
34 microcephaly 10.0
35 lipoid congenital adrenal hyperplasia 10.0
36 oligohydramnios 10.0
37 agammaglobulinemia 10.0
38 tic disorder 10.0
39 coloboma of macula 9.9
40 elastosis perforans serpiginosa 9.9
41 nondisjunction 9.9
42 noonan syndrome 1 9.9
43 radioulnar synostosis, nonsyndromic 9.9
44 neural tube defects 9.9
45 chromosome 2q35 duplication syndrome 9.9
46 syndactyly, type iii 9.9
47 anencephaly 9.9
48 autism 9.9
49 constricting bands, congenital 9.9
50 hydrops fetalis, nonimmune 9.9

Graphical network of the top 20 diseases related to 47,xyy:



Diseases related to 47,xyy

Symptoms & Phenotypes for 47,xyy

Human phenotypes related to 47,xyy:

58 31 (show all 35)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 delayed speech and language development 58 31 hallmark (90%) Very frequent (99-80%) HP:0000750
2 low-set ears 58 31 hallmark (90%) Very frequent (99-80%) HP:0000369
3 motor delay 58 31 hallmark (90%) Very frequent (99-80%) HP:0001270
4 malar flattening 58 31 hallmark (90%) Very frequent (99-80%) HP:0000272
5 tall stature 58 31 hallmark (90%) Very frequent (99-80%) HP:0000098
6 macrocephaly 58 31 frequent (33%) Frequent (79-30%) HP:0000256
7 intellectual disability 58 31 frequent (33%) Frequent (79-30%) HP:0001249
8 hypertelorism 58 31 frequent (33%) Frequent (79-30%) HP:0000316
9 neonatal hypotonia 58 31 frequent (33%) Frequent (79-30%) HP:0001319
10 attention deficit hyperactivity disorder 58 31 frequent (33%) Frequent (79-30%) HP:0007018
11 specific learning disability 58 31 frequent (33%) Frequent (79-30%) HP:0001328
12 asthma 58 31 frequent (33%) Frequent (79-30%) HP:0002099
13 impulsivity 58 31 frequent (33%) Frequent (79-30%) HP:0100710
14 finger clinodactyly 58 31 frequent (33%) Frequent (79-30%) HP:0040019
15 impaired social interactions 58 31 frequent (33%) Frequent (79-30%) HP:0000735
16 congenital stationary night blindness 58 31 frequent (33%) Frequent (79-30%) HP:0007642
17 hydrocephalus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000238
18 macroorchidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000053
19 cryptorchidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000028
20 increased circulating gonadotropin level 58 31 occasional (7.5%) Occasional (29-5%) HP:0000837
21 micropenis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000054
22 azoospermia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000027
23 hypospadias 58 31 occasional (7.5%) Occasional (29-5%) HP:0000047
24 male infertility 58 31 occasional (7.5%) Occasional (29-5%) HP:0003251
25 oligospermia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000798
26 abnormality of brainstem morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0002363
27 dysgenesis of the cerebellar vermis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002195
28 increased serum testosterone level 58 31 occasional (7.5%) Occasional (29-5%) HP:0030088
29 varicocele 58 31 occasional (7.5%) Occasional (29-5%) HP:0012871
30 cerebellar dysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0007033
31 seizure 31 occasional (7.5%) HP:0001250
32 seizures 58 Occasional (29-5%)
33 behavioral abnormality 58 Frequent (79-30%)
34 autistic behavior 58 Occasional (29-5%)
35 hyperactivity 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to 47,xyy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.62 IGFBP3 SRY

Drugs & Therapeutics for 47,xyy

Drugs for 47,xyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
2
Labetalol Approved Phase 4 36894-69-6 3869
3
Ethanol Approved Phase 4 64-17-5 702
4
Ondansetron Approved Phase 4 99614-02-5 4595
5
Fluorouracil Approved Phase 4 51-21-8 3385
6
Cetuximab Approved Phase 4 205923-56-4 56842117 2333
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
8
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
9
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
10 Neurotransmitter Agents Phase 4
11 Adrenergic Agents Phase 4
12 Dermatologic Agents Phase 4
13 Antihypertensive Agents Phase 4
14 Pharmaceutical Solutions Phase 4
15 Sympathomimetics Phase 4
16 Hormones Phase 4
17 Adrenergic alpha-Antagonists Phase 4
18 Adrenergic alpha-1 Receptor Antagonists Phase 4
19 Vasodilator Agents Phase 4
20 Adrenergic Antagonists Phase 4
21 Adrenergic beta-Antagonists Phase 4
22 Gastrointestinal Agents Phase 4
23 Psychotropic Drugs Phase 4
24 Antiemetics Phase 4
25 Anti-Anxiety Agents Phase 4
26 Antipsychotic Agents Phase 4
27 Hydroxycholecalciferols Phase 4
28 Nutrients Phase 4
29 Vitamins Phase 4
30 Calciferol Phase 4
31 Calcium, Dietary Phase 4
32 Anti-Bacterial Agents Phase 4
33 Alkylating Agents Phase 4
34 Antibiotics, Antitubercular Phase 4
35 Immunosuppressive Agents Phase 4
36 Immunologic Factors Phase 4
37 Antineoplastic Agents, Immunological Phase 4
38 Antimetabolites Phase 4
39 Mitomycins Phase 4
40
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
41
Calcium Nutraceutical Phase 4 7440-70-2 271
42
Eliglustat Approved Phase 3 491833-29-5 23652731
43
tannic acid Approved Phase 3 1401-55-4
44
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
45
Azelaic acid Approved Phase 3 123-99-9 2266
46
Mesna Approved, Investigational Phase 3 3375-50-6 598
47
Etoposide Approved Phase 3 33419-42-0 36462
48
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
49
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
50
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule Completed NCT01349829 Phase 4
2 Effects of Nitroglycerin Versus Labetalol on Tissue Perfusion During Deliberate Hypotension for Sinus Endoscopic Surgery. Completed NCT03809065 Phase 4 Nitroglycerin;Labetalol
3 Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial Completed NCT02760069 Phase 4 Inhaled isopropyl alcohol;Oral ondansetron;Inhaled normal saline;Oral placebo
4 Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS Completed NCT03644212 Phase 4 Vitamin D3
5 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
6 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE) Completed NCT00891202 Phase 3 Eliglustat tartrate;Placebo
7 A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea Completed NCT01659853 Phase 3 CD07805/47 gel 0.5%/CD07805/47 Vehicle;azelaic acid gel 15%
8 Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma Completed NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
9 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea Completed NCT01789775 Phase 3 Drug: CD07805/47 gel;CD07805/47 gel Placebo
10 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355471 Phase 3 CD07805/47 Gel;Placebo
11 A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01318733 Phase 3 CD07805/47 gel 0.5%
12 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355458 Phase 3 CD07805/47 gel;Placebo
13 A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United States Licensed Quadrivalent Influenza Virus Vaccine (QIV) in Healthy Subjects 6 Months Through 47 Months Completed NCT04074928 Phase 3
14 A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer Completed NCT00171704 Phase 3 Letrozole;Tamoxifen
15 Randomised, Controlled Clinical Study Regarding the Feasibility of Converting Opiate Dependents From Methadone Substitutes to Slow Release Morphine Sulphate (Sevre-Long™) Completed NCT01079117 Phase 3 Sevre-Long™;Slow release oral morphine;Methadone
16 A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia Completed NCT00288509 Phase 3
17 Phase 3 Study of Vitamin D Analog (Alfacalcidol) on Muscle Strength in Elderly Indonesian Women Who Have Low Handgrip Strength Completed NCT02327091 Phase 3 alfacalcidol
18 A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT02610868 Phase 3 MYOBLOC
19 Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis Completed NCT02207231 Phase 3 Guselkumab 100 mg;Placebo for guselkumab;Adalimumab;Placebo for adalimumab
20 A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months Recruiting NCT03932682 Phase 3
21 Effect of Adjunctive Metformin on Recurrence of Non-DM Colorectal Cancer Stage II High-risk/ III Colorectal Cancer: Open-label Randomized Controlled Recruiting NCT02614339 Phase 3 metformin;control
22 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema Withdrawn NCT01882712 Phase 3 CD07805/47 Gel 0.5%;CD07805/47 Gel Placebo
23 The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark (Cinnamomum Verum and C. Aromaticum) (Cinnamonforce™) - Randomized Placebo-Controlled Clinical Trial Unknown status NCT00479973 Phase 2
24 Effect of CD07805/47 Gel in Subjects Presenting With Flushing Related to Erythematotelangiectatic or Papulopustular Rosacea Completed NCT02300129 Phase 2 CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo;Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo;CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47;Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47
25 A 4-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Investigating the Efficacy and Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily (QD), and CD07805/47 Gel 0.18% Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01174030 Phase 2 CD07805/47 Gel;Vehicle Gel;CD07805/47 Gel;CD07805/47 Gel;Vehicle Gel
26 Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy Completed NCT01091974 Phase 2 armodafinil;Placebo Comparator
27 Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Dose-Finding Study Investigating the Pharmacodynamics and Safety of Three Concentrations of CD07805/47 Topical Gel (0.07%, 0.18%, and 0.50%), Applied in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea Completed NCT00989014 Phase 2 CD07805/47;CD07805/47;CD07805/47;CD07805/47 placebo
28 A Dbl-blind,Randomized,Controlled,Phase IIb Field Trial in 12-47 Month-old Children in Western Kenya to Eval the Efficacy,Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine vs Rabies Vaccine Completed NCT00223990 Phase 2
29 Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer Completed NCT00002774 Phase 2 Tirapazamine;Cisplatin;5-fluorouracil
30 Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium Completed NCT00249990 Phase 2 9-NC in aerosol reservoir
31 A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Interferon Alfa (IFN-α) on Patients With Advanced or Metastatic Renal Cell Cancer Completed NCT00445523 Phase 2 Interferon-alpha
32 Phase II Trial of Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer After Previous Local Therapy. Completed NCT00596895 Phase 2
33 Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma Completed NCT01554059 Phase 2 Bevacizumab;Oxaliplatin;5-FU
34 Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT03325816 Phase 1, Phase 2 Nivolumab
35 Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children Completed NCT01328925 Phase 2 Nitazoxanide
36 Eculizumab to Enable Renal Transplantation in Patients With History of Antiphospholipid Antibody Syndrome or Catastrophic Antiphospholipid Antibody Syndrome Completed NCT01029587 Phase 2 Eculizumab
37 Randomized, Double-blind Placebo-controlled Multi-center Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Psoriatic Arthritis Completed NCT00809614 Phase 2
38 Effect of Thermal Stimulation on Cortical Excitability and Motor Function in Chronic Stroke Patients Completed NCT01407536 Phase 1, Phase 2
39 Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma Recruiting NCT03047928 Phase 1, Phase 2 Nivolumab
40 Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and Older Recruiting NCT04563533 Phase 1, Phase 2
41 A Pilot Study of Low Dose IL-2 in the Treatment of Relapsing Polychondritis Not yet recruiting NCT04077736 Phase 2 Interleukin-2
42 Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica Not yet recruiting NCT04062006 Phase 2 Interleukin-2
43 A Phase II Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer (47-02-001) Terminated NCT00585416 Phase 2 CGC-11047
44 IntraCoronary Treatment With Integrilin To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial Terminated NCT00719914 Phase 2 eptifibatide;eptifibatide;normal saline
45 Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial. Completed NCT00292227 Phase 1 Rotigotine;Moxifloxacin infusion
46 Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine. Completed NCT00317473 Phase 1
47 A 47 Hour, Single Application, Occlusive Forearm Skin Patch Test to Assess, Under Dermatological Control, the Acute Cutaneous Tolerance of Project Storm on the Forearm of Adult Subjects With Dry/Atopic and Very Dry/Atopic Skin Completed NCT02620293 Phase 1
48 A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease Completed NCT00464334 Phase 1
49 A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignancies Recruiting NCT03717103 Phase 1 IBI188;IBI188;IBI188, Rituximab
50 A Phase 1a Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas Active, not recruiting NCT03763149 Phase 1

Search NIH Clinical Center for 47,xyy

Genetic Tests for 47,xyy

Genetic tests related to 47,xyy:

# Genetic test Affiliating Genes
1 Double Y Syndrome 29

Anatomical Context for 47,xyy

MalaCards organs/tissues related to 47,xyy:

40
Prostate, Myeloid, Bone Marrow, Endothelial, Lymph Node, Skin, Liver

Publications for 47,xyy

Articles related to 47,xyy:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Clinical aspects of infertile 47,XYY patients: a retrospective study. 61 20
28715980 2019
2
Oral, physical, and behavioral aspects of patient with chromosome 47, XYY syndrome. 61 20
26381641 2015
3
Positive effects of early androgen therapy on the behavioral phenotype of boys with 47,XXY. 61 20
25939399 2015
4
Differentially-expressed mRNAs, microRNAs and long noncoding RNAs in intervertebral disc degeneration identified by RNA-sequencing. 61
33764282 2021
5
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. 61
33220855 2021
6
Women's experiences using drugs to induce abortion acquired in the informal sector in Colombia: qualitative interviews with users in Bogotá and the Coffee Axis. 61
33734025 2021
7
The plasminogen activating system in the pathogenesis of Alzheimer's disease. 61
33642369 2021
8
Filamentous fungi occurrence on Molossus molossus (Pallas, 1766) (Chiroptera: Molossidae) present in an Atlantic Forest remnant in Southern Brazil. 61
33053139 2021
9
Synthesis of Ni₃Bi₂S₂ Coupled with N-Doped Carbon Sheets as Electrocatalyst for Triiodide and Oxygen Reduction. 61
33691860 2021
10
The Effect of Grain Boundary on Electrical Characteristics in the Source and Drain Regions of Polycrystalline Silicon Based in One Transistor Dynamic Random Access Memory. 61
33714312 2021
11
A biotechnological tool for glycoprotein desialylation based on immobilized neuraminidase from Clostridium perfringens. 61
33732900 2021
12
Mixed and disseminated paracoccidioidomycosis after liver transplantation: Case report. 61
33717862 2021
13
Partial corneal recovery following selective trabeculoplasty-induced keratopathy: Longitudinal analysis through scheimpflug imaging. 61
33718663 2021
14
Unnatural-cause mortality patterns of Northern Finnish men and women diverge in adolescence - A 52-year follow-up. 61
33717861 2021
15
Emotional working memory updating in individuals with borderline personality features. 61
33476888 2021
16
The effects of blanching on composition and modification of proteins in navy beans (Phaseolus vulgaris). 61
33465570 2021
17
A 313 plastome phylogenomic analysis of Pooideae: Exploring relationships among the largest subfamily of grasses. 61
33609709 2021
18
Acid stable α-amylase from Pseudomonas balearica VITPS19-Production, purification and characterization. 61
33747801 2021
19
Tracing riverine dissolved organic carbon and its transport to the halocline layer in the Chukchi Sea (western Arctic Ocean) using humic-like fluorescence fingerprinting. 61
33581529 2021
20
Understanding spatial and temporal variability of N leaching reduction by winter cover crops under climate change. 61
33736187 2021
21
Development and validation of the Reasons Individuals Stop Eating Questionnaire (RISE-Q): A novel tool to characterize satiation. 61
33460694 2021
22
Brominated flame retardants (BFRs) in marine food webs from Bohai Sea, China. 61
33578148 2021
23
Molecular profiles of naphthenic acid fraction compounds from mine lease wetlands in the Athabasca Oil Sands Region. 61
33601202 2021
24
Impact of postmortem degradation of cytoskeletal proteins on intracellular gap, drip channel and water-holding capacity. 61
33667879 2021
25
Treatment prescription, adherence, and persistence after the first hospitalization for heart failure: A population-based retrospective study on 100785 patients. 61
33582198 2021
26
Development of a list of potentially inappropriate medications for patients with heart failure (PIMHF). 61
32753266 2021
27
Prevention of variceal rebleeding in cirrhotic patients with spontaneous portosystemic shunts: transjugular intrahepatic portosystemic shunt versus endoscopic treatment. 61
33731589 2021
28
The relationship between histologic chorioamnionitis and decidual macrophage polarization and their influence on outcomes of neonates born before the 32nd gestational week. 61
31258026 2021
29
Advanced ovarian cancer patients identify opportunities for prehabilitation: A qualitative study. 61
33718562 2021
30
Expression, purification and immunological characterization of recombinant nucleocapsid protein fragment from SARS-CoV-2. 61
33582454 2021
31
Use of ring-enhancement and focal necrosis to differentiate pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma on CT and MRI. 61
33387918 2021
32
Beneficial contribution of induced pluripotent stem cell-progeny to Connexin 47 dynamics during demyelination-remyelination. 61
33301181 2021
33
Genetic architecture and adaptation of flowering time among environments. 61
33484593 2021
34
Survey on medication information literacy and influencing factors among pregnant Chinese women. 61
31331258 2021
35
Chronic adolescent stress causes sustained impairment of cognitive flexibility and hippocampal synaptic strength in female rats. 61
33614865 2021
36
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases. 61
33722933 2021
37
Current status of home monitoring technology for age-related macular degeneration. 61
33710010 2021
38
TGM6 might not be a specific causative gene for spinocerebellar ataxia resulting from genetic analysis and functional study. 61
33588035 2021
39
Elisabeth Kübler-Ross and the "Five Stages" Model in a Sampling of Recent Textbooks Published in 10 Countries Outside the United States. 61
30975028 2021
40
"Vital in today's time": Evaluation of a disaster table-top exercise for pharmacists and pharmacy staff. 61
33773638 2021
41
Rescue Protocol to Improve the Image Quality of 18F-FDG PET/CT Myocardial Metabolic Imaging. 61
33661201 2021
42
Sex differences in the elevated plus-maze test and large open field test in adult Wistar rats. 61
33684454 2021
43
Patient perspectives on how to improve education on medication side effects: cross-sectional observational study at a rheumatology clinic in The Netherlands. 61
33730208 2021
44
Defining the characteristics of physically demanding winch rescue in helicopter search and rescue operations. 61
33540207 2021
45
Long-range transport of ozone across the eastern China seas: A case study in coastal cities in southeastern China. 61
33454482 2021
46
Midwife-performed checklist and ultrasound to identify obstetric conditions at labour triage in Uganda: A quasi-experimental study. 61
33631411 2021
47
Coxiella burnetii in the environment: A systematic review and critical appraisal of sampling methods. 61
33314733 2021
48
Catheter-obtained, Enterococcus and Proteus positive urine cultures may represent mostly contamination or asymptomatic bacteriuria in infants <90 days. 61
33620253 2021
49
Ultrasound-assisted modification of rutin to nanocrystals and its application in barley starch pyrodextrinization. 61
33243560 2021
50
Roles of endoplasmic reticulum stress in 2,2',4,4'-tetrabromodiphenylether-induced thyroid cell apoptosis and autophagy. 61
33647853 2021

Variations for 47,xyy

Expression for 47,xyy

Search GEO for disease gene expression data for 47,xyy.

Pathways for 47,xyy

GO Terms for 47,xyy

Sources for 47,xyy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....